Healthcare provider profile · identity verified

Noleen V Kala, MD

Internal Medicine · URBANA, IL · NPI 1578596276

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	676	222
Levothyroxine Sodium	Levothyroxine Sodium	512	139
Lisinopril	Lisinopril	416	120
Losartan Potassium	Losartan Potassium	404	149
Amlodipine Besylate	Amlodipine Besylate	389	142
Omeprazole	Omeprazole	308	104
Furosemide	Furosemide	274	90
Simvastatin	Simvastatin	257	79
Gabapentin	Gabapentin	231	62
Potassium Chloride	Potassium Chloride	230	62
Metoprolol Succinate	Metoprolol Succinate	222	70
Duloxetine Hcl	Duloxetine Hcl	187	55
Fluticasone Propionate	Fluticasone Propionate	178	64
Rosuvastatin Calcium	Rosuvastatin Calcium	167	44
Ozempic	Semaglutide	151	29
Carvedilol	Carvedilol	147	55
Famotidine	Famotidine	144	43
Metoprolol Tartrate	Metoprolol Tartrate	139	39
Hydrochlorothiazide	Hydrochlorothiazide	135	55
Pantoprazole Sodium	Pantoprazole Sodium	131	42
Metformin Hcl	Metformin Hcl	120	46
Trazodone Hcl	Trazodone Hcl	111	34
Alendronate Sodium	Alendronate Sodium	109	36
Warfarin Sodium	Warfarin Sodium	108	24
Pravastatin Sodium	Pravastatin Sodium	105	29
Citalopram Hbr	Citalopram Hydrobromide	99	32
Albuterol Sulfate Hfa	Albuterol Sulfate	95	49
Eliquis	Apixaban	89	34
Sertraline Hcl	Sertraline Hcl	85	35
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	81	32
Tramadol Hcl	Tramadol Hcl	80	31
Tizanidine Hcl	Tizanidine Hcl	78	40
Metformin Hcl Er	Metformin Hcl	75	23
Glipizide Er	Glipizide	71	27
Buspirone Hcl	Buspirone Hcl	69	22
Lorazepam	Lorazepam	63	26
Escitalopram Oxalate	Escitalopram Oxalate	60	21
Jardiance	Empagliflozin	60	15
Hydralazine Hcl	Hydralazine Hcl	59	18
Clopidogrel	Clopidogrel Bisulfate	57	20
Ezetimibe	Ezetimibe	57	17
Spironolactone	Spironolactone	55	17
Doxycycline Monohydrate	Doxycycline Monohydrate	54	44
Tamsulosin Hcl	Tamsulosin Hcl	52	23
Triamcinolone Acetonide	Triamcinolone Acetonide	48	39
Allopurinol	Allopurinol	47	20
Meloxicam	Meloxicam	47	27
Memantine Hcl	Memantine Hcl	45	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	45	14
Mounjaro	Tirzepatide	42	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	42	16
Acetaminophen-Codeine	Acetaminophen With Codeine	40	17
Atenolol	Atenolol	40	12
Pregabalin	Pregabalin	39	suppressed
Diclofenac Sodium	Diclofenac Sodium	38	15
Bupropion Xl	Bupropion Hcl	37	13
Prednisone	Prednisone	37	26
Ropinirole Hcl	Ropinirole Hcl	37	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	37	suppressed
Cephalexin	Cephalexin	35	31
Myrbetriq	Mirabegron	35	suppressed
Donepezil Hcl	Donepezil Hcl	33	suppressed
Estradiol	Estradiol	32	suppressed
Glipizide	Glipizide	32	13
Isosorbide Mononitrate Er	Isosorbide Mononitrate	31	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	31	suppressed
Ondansetron Odt	Ondansetron	31	18
Oxybutynin Chloride	Oxybutynin Chloride	29	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	29	suppressed
Valsartan	Valsartan	29	suppressed
Azithromycin	Azithromycin	28	25
Montelukast Sodium	Montelukast Sodium	28	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	27	suppressed
Klor-Con M20	Potassium Chloride	27	11
Verapamil Er	Verapamil Hcl	27	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	26	suppressed
Clonazepam	Clonazepam	26	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	26	14
Propranolol Hcl	Propranolol Hcl	26	suppressed
Bupropion Hcl Sr	Bupropion Hcl	25	suppressed
Azelastine Hcl	Azelastine Hcl	24	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Nystatin	Nystatin	24	14
Amitriptyline Hcl	Amitriptyline Hcl	23	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	13
Torsemide	Torsemide	23	suppressed
Valacyclovir	Valacyclovir Hcl	23	suppressed
Lovastatin	Lovastatin	22	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	21	19
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	21	suppressed
Trulicity	Dulaglutide	21	suppressed
Xarelto	Rivaroxaban	21	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	19
Celecoxib	Celecoxib	20	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Fluconazole	Fluconazole	19	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	19	suppressed
Meclizine Hcl	Meclizine Hcl	19	12
Synthroid	Levothyroxine Sodium	19	suppressed
Ventolin Hfa	Albuterol Sulfate	19	11
Acyclovir	Acyclovir	18	suppressed
Lactulose	Lactulose	18	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Amiloride Hcl	Amiloride Hcl	16	suppressed
Dulera	Mometasone/Formoterol	16	suppressed
Finasteride	Finasteride	16	suppressed
Nitroglycerin	Nitroglycerin	16	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	16	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Ciclopirox	Ciclopirox	13	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Vancomycin Hcl	Vancomycin Hcl	13	suppressed
Varenicline Tartrate	Varenicline Tartrate	13	suppressed
Alprazolam	Alprazolam	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Temazepam	Temazepam	12	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error